Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

EXCLAIM: Onderzoek naar gecombineerde lokale en systemische benaderingen bij hersenmetastasen: een gerandomiseerde fase II-studie met meerdere cohorten ter evaluatie van de initiële respons op systemische therapie en de daaropvolgende integratie van stereotactische radiochirurgie bij patiënten met hersenmetastasen met een laag risico en een actief centraal zenuwstelsel

5 oktober 2026 bijgewerkt door: M.D. Anderson Cancer Center

EXCLAIM: Onderzoek naar gecombineerde lokale en systemische benaderingen bij hersenmetastasen: een multi-cohort gerandomiseerde fase II-studie ter evaluatie van de initiële respons op systemische therapie en de daaropvolgende integratie van stereotactische radiochirurgie bij patiënten met hersenmetastasen met een laag risico en opties voor centrale zenuwstelsel-actieve systemische therapie

To learn if consolidative stereotactic radiosurgery (cSRS) can help to control central nervous system (CNS) disease in patients who have brain metastases and have a partial response or stable brain metastases after systemic therapy.

To learn if using SRS to treat all brain metastases that do not respond to systemic therapy versus treating only metastases that are getting worse can help to control CNS disease in patients whose disease gets worse after systemic therapy.

Studie Overzicht

Toestand

Werving

Conditie

Gedetailleerde beschrijving

Primary Objectives:

To assess whether cSRS improves CNS progression-free survival (CNS-PFS) in patients with BM who have a PR or SD with upfront systemic therapy.

To assess whether SRS to all BM not in CR (cSRS + pdSRS) versus only progressing lesions (pdSRS) improves CNS-PFS in patients with CNS progression on upfront systemic therapy.

Secondary Objectives:

To report the rate and degree of response of BM to systemic therapy by specific regimen and histology.

To report adverse neurologic events that occur with BM treated with upfront systemic therapy and differences in these events between various downstream radiation therapy options (omission, cSRS, pdSRS, etc).

To evaluate rates of LMD in all patients managed with upfront systemic therapy and differences in LMD rates between various downstream radiation therapy options (omission, cSRS, pdSRS, etc).

To evaluate neurocognitive changes in patients treated with upfront systemic therapy for BMand differences in these changes between various downstream radiation therapy options (omission, cSRS, pdSRS, etc).

To perform inference on overall survival as estimated by the Kaplan-Meier estimator in patients treated with upfront systemic therapy for BM and differences in these changes between various downstream radiation therapy options (omission, cSRS, pdSRS, etc).

Exploratory Objectives:

To correlate imaging biomarkers with outcomes of BM treated with systemic therapy.

To correlate volumetric assessment of lesion response to conventional assessment by mRECIST 1.1.

To explore ML as a tool to predict outcomes of BM treatment based on disease specific, clinical, and lesion specific features.

To explore the association of circulating bioanalytes with up front systemic therapy for BM and subsequent downstream management strategies (i.e. cSRS).

Studietype

Ingrijpend

Inschrijving (Geschat)

316

Fase

  • Fase 2

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

    • Texas
      • Houston, Texas, Verenigde Staten, 77030
        • Werving
        • The University of Texas MD Anderson Cancer Center
        • Contact:
        • Hoofdonderzoeker:
          • Thomas H Beckham, MD,PHD

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  1. Age ≥ 18 years.
  2. Evaluation by a brain metastasis multidisciplinary team (BM-MDT) consisting of a medical oncologist (can be the patient's primary medical oncologist), a radiation oncologist who regularly performs SRS, and a neurosurgeon. This evaluation can take place in clinic or during a multidisciplinary conference.
  3. Life expectancy > 6 months as estimated by BM-MDT.
  4. BM-MDT agreement that the planned systemic therapy regimen may provide intracranial benefit (SD, PR, or CR in the CNS).
  5. BM-MDT agreement that the patient's BM does not require immediate local therapy (surgery and/or radiation therapy); i.e. it is judged to be safe to omit local therapy as initial BM management.
  6. The patient's BM are amenable to SRS as initial local therapy as determined by BM-MDT.
  7. Subjects must have signed and dated an IRB/IEC approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol-related procedures that are not part of normal subject care.
  8. Histologically confirmed metastatic cancer with at least one measurable metastasis in the brain (≥ 5 mm).
  9. At least one measurable intracranial target lesion which was not previously treated with SRS. Regrowth in a cavity of previously excised lesion will not qualify as a measurable lesion. Growth or change in a lesion previously irradiated will not qualify as a measurable lesion.
  10. Prior SRS and prior excision of BM is permitted if other measurable non irradiated lesions as described in #9 remain.
  11. The resection cavity of excised BM must have received appropriate radiation therapy (pre or post operative SRS, brachytherapy) or have been observed for >6 months after resection without evidence of local cavity recurrence.
  12. Subjects must be free of neurologic signs and symptoms related to metastatic brain lesions either without systemic corticosteroids or requiring ≤ 2 mg dexamethasone daily for symptom resolution.
  13. ECOG performance status ≤ 1.
  14. Documented agreement by the patient's primary medical oncologist with the appropriateness of planned SST regimen.
  15. This study will allow non-English speaking subjects to be enrolled. Verbal Translation Preparative Sheet (VTPS) will be used if a translated consent form is not available in the subject's language. The consent form will be translated into the language of the subject after 2 or more occurrences. This will apply to any MD Anderson patient.

Exclusion Criteria:

  1. History of known leptomeningeal involvement (radiographic or cytological).
  2. Small cell lung cancer, lymphoma, or leukemia histology.
  3. Non-small cell lung cancer histology with targetable oncogenic driver mutation with planned initiation of highly CNS active targeted therapy (eg osimertinib, brigatinib, alectinib, or lorlatinib).
  4. Subjects previously treated with WBRT.
  5. Any intact BM size > 3 cm. After surgical excision and appropriate radiation therapy to the cavity, patients may enroll if additional eligible lesions are present.
  6. Prior disease progression on one or more of the agents comprising SST.
  7. Exposure to one or more agents comprising SST within the last 30 days.
  8. Prior unacceptable toxicity during treatment with one or more agents comprising SST.
  9. Subjects with a major medical, neurologic or psychiatric condition who are judged as unable to fully comply with study therapy or assessments should not be enrolled.
  10. History of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years. Note: The time requirement does not apply to participants who underwent successful treatment of superficial bladder cancer, in situ cervical cancer, ductal carcinoma in situ, or other in-situ cancers. Subjects with a completely treated prior malignancy and no evidence of disease for ≥ 2 years are eligible.
  11. Skin Cancer Exclusion: Please note that localized cutaneous basal cell carcinoma and squamous cell carcinoma is not an exclusion criterion regardless of treatment status. Biopsy proven metastatic disease from these histologies is an exclusion criterion if this constitutes a second cancer.
  12. Patient weight >450 pounds.
  13. Patient had prior SRS to any intracranial lesion <15mm from a metastasis on the screening MRI. Prior MRIs and DICOMs will be used to make this determination.
  14. Patient unable to receive a brain MRI (implanted metal devices or foreign bodies) or MRI contrast.
  15. Any BM with a significant hemorrhagic component (defined as MRI T1 intrinsic hyperintensity comprising ≥ 25% of maximal lesion diameter).

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: cSRS PR or SD

Patients with a CR will be observed with ongoing standard of care MRI. Patients with SD or PR will be randomized to receive cSRS or ongoing observation.

Participants will receive systemic therapy as a standard of care therapeutic option

Participants will receive systemic therapy as a standard of care therapeutic option

Experimenteel: a-pdSR CNS PD

At the time of CNS PD, patients will also be randomized to pdSRS versus pdSRS + cSRS.

Participants will receive systemic therapy as a standard of care therapeutic option

Participants will receive systemic therapy as a standard of care therapeutic option

Experimenteel: b-PDC CNS PD

At the time of CNS PD, patients will also be randomized to pdSRS versus pdSRS + cSRS.

Participants will receive systemic therapy as a standard of care therapeutic option

Participants will receive systemic therapy as a standard of care therapeutic option

Experimenteel: SST treated SD or PR patients to receive cSRS/ ongoing observation

Patients with a CR will be observed with ongoing standard of care MRI. Patients with SD or PR will be randomized to receive cSRS or ongoing observation.

Participants will receive systemic therapy as a standard of care therapeutic option

Participants will receive systemic therapy as a standard of care therapeutic option

Experimenteel: SST treated PD patients to pdSRS / pdSRS+cSRS

At the time of CNS PD, patients will also be randomized to pdSRS versus pdSRS + cSRS.

Participants will receive systemic therapy as a standard of care therapeutic option

Participants will receive systemic therapy as a standard of care therapeutic option

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Safety and Adverse Events (AEs).
Tijdsspanne: Through study completion; an average of 1 year.

Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

Through study completion; an average of 1 year.

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Thomas H Beckham, MD,PHD, M.D. Anderson Cancer Center

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

14 februari 2025

Primaire voltooiing (Geschat)

30 september 2028

Studie voltooiing (Geschat)

30 september 2030

Studieregistratiedata

Eerst ingediend

17 oktober 2024

Eerst ingediend dat voldeed aan de QC-criteria

17 oktober 2024

Eerst geplaatst (Werkelijk)

18 oktober 2024

Updates van studierecords

Laatste update geplaatst (Werkelijk)

6 oktober 2026

Laatste update ingediend die voldeed aan QC-criteria

5 oktober 2026

Laatst geverifieerd

1 oktober 2026

Meer informatie

Termen gerelateerd aan deze studie

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren